Replies to post #92623 on Ayala Pharmaceuticals Inc (ADXS)

[investorluck]

It was stated that they would use Keytruda in this study:
The Company also continues to progress its ADXS-HOT 503 drug candidate, expressing public (shared) tumor antigens both as monotherapy and in combination with KEYTRUDA® for the treatment of non-small cell lung cancer (NSCLC).

from:
https://ir.advaxis.com/press-release/clinical-data-updates/advaxis-provides-update-clinical-pipeline

I wonder what drove the change.

[hovacre]

Aha there it is. Slipped my attention.

For the record, it will almost certainly be a PD-1 inhibitor. The PD-L1 antibodies are either moribund (avelumab), or we've apparently developed some antipathy with the developer (durvalumab)